Gustavo Harrow has been diagnosed with a malignancy that affects hematopoiesis.…
- User
Gustavo Harrow has been diagnosed with a malignancy that affects hematopoiesis. Treatment is bone marrow transfer. Wishing to help, you send a spit sample to the National Marrow Donor Program to see if you are immunologically compatible to be his donor.
You and Gustavo are sufficiently matched to carry out a bone marrow transfer from you to him!
What cell type should physicians isolate from you to restore Gustavo’s immune system?
- Assistant
The cell type that physicians should isolate from you to restore Gustavo's immune system is hematopoietic stem cells (HSCs). These cells have the ability to differentiate into various types of blood cells, including red blood cells, white blood cells, and platelets. By transferring your HSCs to Gustavo, his immune system can be restored and function properly.
- User
What isolation procedure should hematologists follow to obtain these cells? What specific cell markers would you use? To answer this question, please use the information in Table 2-4 of the textbook and the lecture slides.
- Assistant
To obtain hematopoietic stem cells (HSCs), hematologists can follow the procedure of bone marrow aspiration or peripheral blood stem cell (PBSC) collection.
Bone marrow aspiration: This procedure involves the use of a needle to collect bone marrow directly from the bones, typically from the iliac crest (hip bone), under local anesthesia. The aspirated bone marrow contains HSCs along with other types of blood cells.
Peripheral blood stem cell (PBSC) collection: This procedure involves the stimulation and mobilization of HSCs from the bone marrow into the bloodstream. This is done by administering growth factors like G-CSF (granulocyte colony-stimulating factor) or GM-CSF (granulocyte-macrophage colony-stimulating factor) to the donor for several days. The mobilized HSCs can then be collected from the circulating blood using a procedure called apheresis.
To identify and isolate hematopoietic stem cells, hematologists can use specific cell markers. CD34 is one of the most common cell markers used to identify and isolate HSCs.
CD34 is expressed on the surface of HSCs as well as on other progenitor cells. Therefore, additional markers are used to further purify the HSC population. CD38, a negative marker, is used in combination with CD34 to eliminate more mature progenitor cells, as they tend to express CD34 and CD38 simultaneously.
In addition to CD34 and CD38, other markers like CD45RA, CD71, and HLA-DR can be used to further characterize and isolate specific subsets of HSCs based on their differentiation potential and functional properties.
The specific combination of cell markers and the isolation technique used may vary depending on the laboratory protocols and preferences of the hematologists.
- User
What isolation procedure for isolating hematopoietic stem cells
- Assistant
One commonly used isolation procedure for isolating hematopoietic stem cells (HSCs) is the apheresis technique. Apheresis involves collecting specific blood components, including HSCs, from the donor's peripheral blood.
To perform the apheresis procedure for HSC isolation, the following steps are typically followed:
-
Mobilization: The donor is given growth factors such as G-CSF (granulocyte colony-stimulating factor) or GM-CSF (granulocyte-macrophage colony-stimulating factor) to stimulate the production and release of HSCs from the bone marrow into the peripheral blood.
-
Collection of blood: Blood is drawn from the donor's vein using a needle. This is usually done through a procedure called peripheral venous access. The blood is collected into an apheresis machine that separates the different blood components.
-
Separation of HSCs: Within the apheresis machine, specialized filters and centrifugation techniques are used to isolate the HSCs from the other blood components. The machine separates the targeted HSC population from the rest of the blood, which includes red blood cells, platelets, and plasma. The specific process and machinery used can vary among different apheresis systems.
-
Collection of HSCs: The isolated HSCs are collected and stored in a separate bag or container in a sterile manner.
After the HSCs are isolated, they can be further processed, tested, and prepared for transplantation into Gustavo for the bone marrow transfer. The HSCs can be cryopreserved (frozen) until they are required for transplantation.
It's important to note that the specific isolation procedure or technique used may vary depending on the hospital or transplant center's protocols and preferences. The apheresis technique is commonly employed due to its ability to efficiently collect a sufficient number of HSCs while minimizing risk to the donor.
-
- User
Bone marrow transplants can also cure rare genetic diseases that affect hematopoiesis at birth. What cell types could be affected by conditions that interfere with Granulocyte maturation
- Assistant
Conditions that interfere with granulocyte maturation can affect various cell types involved in hematopoiesis. Granulocytes are a type of white blood cell that includes neutrophils, eosinophils, and basophils. These cells are formed from granulocyte precursor cells in the bone marrow, and any disruption in their maturation process can lead to abnormal or reduced production of mature granulocytes.
The following cell types can be affected in conditions that interfere with granulocyte maturation:
-
Granulocyte precursors: The maturation process of granulocytes starts with precursor cells in the bone marrow. Conditions that interfere with granulocyte maturation can disrupt the differentiation and maturation of these granulocyte precursors, resulting in impaired or abnormal development of granulocytes.
-
Promyelocytes: Promyelocytes are the earliest recognizable stage of granulocyte development. They have characteristic features such as a large nucleus with nucleoli and abundant azurophilic granules. Conditions affecting granulocyte maturation can lead to the accumulation of abnormal promyelocytes or their inability to progress to the subsequent stages of maturation.
-
Myelocytes: Myelocytes are the following stage of granulocyte maturation after promyelocytes. They have a more condensed nucleus compared to promyelocytes and develop specific granules such as neutrophilic, eosinophilic, or basophilic granules, depending on the specific type of granulocyte. Conditions that interfere with granulocyte maturation can result in abnormal or reduced production of myelocytes.
-
Metamyelocytes: Metamyelocytes are the intermediate stage between myelocytes and mature granulocytes. They have a kidney-shaped nucleus and show more condensed chromatin compared to myelocytes. Conditions affecting granulocyte maturation can result in a decreased number or abnormal appearance of metamyelocytes.
-
Mature granulocytes: Ultimately, conditions that interfere with granulocyte maturation may lead to a decreased number or dysfunction of mature granulocytes, such as neutrophils, eosinophils, or basophils. This can result in impaired immune system function and increased susceptibility to infections.
It is important to diagnose and treat these genetic diseases affecting granulocyte maturation early to ensure appropriate management and potential curative treatments such as bone marrow transplants.
-
- User
If a genetic disease affects Granulocyte and Dendritic cell maturation but not B cell maturation, what progenitor cell could exhibit the developmental defect?
- Assistant
If a genetic disease affects granulocyte and dendritic cell maturation but not B cell maturation, the progenitor cell that could exhibit the developmental defect is the common myeloid progenitor (CMP). The CMP is a multipotent progenitor cell in the bone marrow that gives rise to various myeloid lineage cells, including granulocytes, monocytes, and dendritic cells.
In normal hematopoiesis, the CMP differentiates into granulocyte-monocyte progenitors (GMPs) and common dendritic cell progenitors (CDPs) under the influence of specific growth factors and transcription factors. GMPs further differentiate into granulocytes (neutrophils, eosinophils, basophils) and monocytes. CDPs give rise to dendritic cells.
However, in the case of a genetic disease affecting granulocyte and dendritic cell maturation, but not B cell maturation, the defect likely lies in the CMP itself or in the molecular factors that regulate its differentiation into GMPs and CDPs.
This defect can disrupt the normal differentiation and maturation of GMPs, leading to impaired development of granulocytes. It can also interfere with the differentiation and maturation of CDPs, resulting in abnormal or reduced production of dendritic cells.
Overall, the defect in the genetic disease affects the myeloid lineage of hematopoiesis, specifically affecting granulocyte and dendritic cell maturation, but leaving B cell maturation unaffected.
- User
If a genetic disease affects Granulocyte and Dendritic cell maturation but not B cell maturation, what progenitor cell could exhibit the developmental defect?
- Assistant
If a genetic disease affects granulocyte and dendritic cell maturation but not B cell maturation, the progenitor cell that could exhibit the developmental defect is the common myeloid progenitor (CMP). The CMP is a multipotent progenitor cell found in the bone marrow responsible for giving rise to cells of the myeloid lineage, including granulocytes and monocytes, as well as dendritic cells.
Under normal circumstances, the CMP differentiates into different progenitor cells, including the granulocyte-monocyte progenitor (GMP) and the common dendritic cell progenitor (CDP). The GMP further differentiates into granulocytes (such as neutrophils, eosinophils, and basophils) and monocytes, while the CDP gives rise to dendritic cells.
In the case of a genetic disease affecting granulocyte and dendritic cell maturation but not B cell maturation, the defect likely occurs at the level of the CMP or its immediate progeny. The genetic abnormality can disrupt the normal differentiation of the CMP into GMP and CDP or the subsequent maturation and function of these progenitor cells.
As a result, the affected individual would experience impaired development of granulocytes and dendritic cells, leading to immune system dysregulation and deficiencies specifically affecting these cell types. However, B cell maturation would remain unaffected as it arises from a different progenitor cell lineage, the common lymphoid progenitor (CLP), which follows a distinct developmental pathway in hematopoiesis.
- User
Researchers wishing to understand the function of various TLRs have two powerful tools: 1) mouse strains engineered with TLR gene deletions. These strains include those with all TLR genes knocked out except one and 2) bacterial mutant strains with mutations in just about any gene of its genes.
Using these tools, design a simple experiment to verify the identity of the ligand for TLR5. State 1) the goal of the experiment, 2) what bacterial mutant genes will be used, and 3) the type of mutation(s) found in the mouse strains you will utilize. Describe the expected results and any controls used in the experiment. Please use a simple table showing your experimental design and anticipated results that would confirm the ligand for TLR5.
- Assistant
Goal of the experiment: The goal of the experiment is to verify the identity of the ligand for Toll-like receptor 5 (TLR5).
Bacterial mutant genes: In order to identify the ligand for TLR5, different bacterial mutant strains will be used. These mutant strains will carry specific mutations in various genes of the bacteria.
Type of mutations in mouse strains: In this experiment, mouse strains with TLR5 gene deletions will be utilized. These mouse strains will have the TLR5 gene knocked out, meaning they will lack the functional TLR5 receptor.
Experimental Design:
Experimental Groups Mouse Strains Bacterial Mutant Strains Group 1 Wild-type mice (with functional TLR5) - Group 2 TLR5 Knockout mice Mutant strain A Group 3 TLR5 Knockout mice Mutant strain B Group 4 TLR5 Knockout mice Mutant strain C
Expected Results:
If the ligand for TLR5 is present in Mutant Strain A:
- In Group 1 (wild-type mice), activation of TLR5 will occur upon exposure to Mutant Strain A, leading to an immune response.
- In Group 2 (TLR5 knockout mice), there will be no response since TLR5 is absent.
If the ligand for TLR5 is present in Mutant Strain B:
- In Group 1 (wild-type mice), activation of TLR5 will occur upon exposure to Mutant Strain B, leading to an immune response.
- In Group 3 (TLR5 knockout mice), there will be no response since TLR5 is absent.
If the ligand for TLR5 is present in Mutant Strain C:
- In Group 1 (wild-type mice), activation of TLR5 will occur upon exposure to Mutant Strain C, leading to an immune response.
- In Group 4 (TLR5 knockout mice), there will be no response since TLR5 is absent.
Controls: To ensure the validity of the results, appropriate controls should be included in the experiment. These controls may include:
- Positive control: Use a known ligand for TLR5 (e.g. a purified flagellin protein) to validate the functionality of TLR5 in the wild-type mouse group.
- Negative control: Use a non-stimulatory mutant bacterial strain lacking ligands for TLR5 to confirm the absence of immune response in all groups.
By comparing the immune response in the control and experimental groups, it will be possible to identify the bacterial mutant strain that activates TLR5, confirming it as the ligand for TLR5.